Canopy Growth (CGC) vs MediWound (MDWD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MediWound (MDWD) has outperformed Canopy Growth (CGC) over the past year, losing 29.5% versus a loss of 44.7%. Over five years, MDWD leads with a -48.0% price change compared with -99.4% for CGC. Canopy Growth is the larger company by market cap ($372.9 million vs $162.8 million), about 2.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGC | MDWD |
|---|---|---|
| Share price | $0.83 | $12.61 |
| Market cap | $372.92M | $162.80M |
| 1-day change | -1.98% | +1.53% |
| YTD return | -25.72% | -32.72% |
| 1-year return | -44.65% | -29.53% |
| 5-year return | -99.37% | -47.97% |
| EPS (TTM) | $-0.45 | $-2.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.38 | $20.03 |
| 52-week low | $0.81 | $12.42 |
| Distance from 52-week high | -65.13% | -37.04% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +44.58% | +143.22% |
| Average volume | 2.77M | 84.67K |
| Shares outstanding | 423.04M | 12.91M |
| Employees | 1,128 | 121 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Canopy Growth is about 2.3 times larger than MediWound by market value ($372.92M vs $162.80M).
- MDWD has outperformed CGC by 15.1 percentage points over the past year.
About Canopy Growth
CGC stock →Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-related products for medical and adult use in Canada, Germany, the United States, and internationally. The company operates through two segments, Cannabis and Storz & Bickel.
Health Care · Medicinal Chemicals and Botanical Products · 1,128 employees
About MediWound
MDWD stock →MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Health Care · Medicinal Chemicals and Botanical Products · 121 employees
CGC vs MDWD FAQ
Which is bigger, Canopy Growth or MediWound?
Canopy Growth (CGC) is larger, with a market capitalization of $372.92M compared with $162.80M for MediWound (MDWD).
Which stock has performed better over the past year, CGC or MDWD?
MDWD returned -29.53% over the past 12 months, compared with -44.65% for CGC (price return, excluding dividends). Past performance does not predict future results.
Are Canopy Growth and MediWound in the same industry?
Yes. Both are classified in the Medicinal Chemicals and Botanical Products industry within the Health Care sector.